Dr. Reckamp Discusses Heat Shock Proteins in Lung Cancer

Karen Reckamp, MD, MS
Published Online: Wednesday, August 17, 2011
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses the use of heat shock proteins in the treatment of lung cancer.

Reckamp explains that heat shock proteins act as chaperone proteins that permit oncoproteins to function. The proteins work as an alternative to inhibiting the tyrosine kinase pathway and are involved in multiple lung cancer related signalling pathways such as EGFR, RAS, ALK, and MET. Heat shock proteins can be used when resistance to other methods are developed.
Online CME Activities
Free CME from PER
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
Cancer Summaries and Commentaries: Updates From San Francisco in Multiple Myeloma
10th International Symposium on Ovarian Cancer and Gynecologic Malignancies® Medical Crossfire®
Community Practice Connections: 12th Annual International Congress on Targeted Therapies in Cancer®
More Reading
$auto_registration$